Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Radnostix, Inc. (INIS : OTC)

• Company Description    Radnostix Inc. manufactures a wide range of radioisotope focused products. The company manufactures and supplies generic sodium iodide I-131 radio-pharmaceutical drug product for hyperthyroidism and thyroid cancer. It also manufactures Cobalt-60 sealed source products. Radnostix Inc., formerly known as International Isotopes Inc., is based in IDAHO FALLS, Idaho. Number of Employees: 45

• Price / Volume Information    Yesterday's Closing Price: $0.07 Daily Weekly Monthly 20 Day Moving Average: 53,699 shares Shares Outstanding: 529.13 (millions) Market Capitalization: $38.68 (millions) Beta: 1.12 52 Week High: $0.11 52 Week Low: $0.05 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -7.47% -11.99% 12 Week -18.78% -24.91% Year To Date 19.25% 18.49%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 4137 COMMERCE CIRCLE - IDAHO FALLS,ID 83401 USA ph: 208-524-5300 fax: 208-524-1411 ir@intisoid.com http://www.radnostix.com

• General Corporate Information    Officers Shahe Bagerdjian - Chief Executive Officer and President Christopher Grosso - Chairman W. Matthew Cox - Chief Financial Officer Robert Atcher - Director Steve Laflin - Director Peer Information Radnostix, Inc. (GSAC) Radnostix, Inc. (CASIF) Radnostix, Inc. (ALCD.) Radnostix, Inc. (OMNN) Radnostix, Inc. (CGPI.) Radnostix, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 45972C102 SIC: 3823 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/12/26 Share - Related Items Shares Outstanding: 529.13 Most Recent Split Date: (:1) Beta: 1.12 Market Capitalization: $38.68 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 14.62 Price/Cash Flow: - Price / Sales: 3.17 EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -26.55% vs. Previous Quarter: -17.91% ROE 03/31/26 - -58.34 12/31/25 - -22.18 09/30/25 - -5.44 ROA 03/31/26 - -12.19 12/31/25 - -5.14 09/30/25 - -1.32 Current Ratio 03/31/26 - 0.88 12/31/25 - 1.16 09/30/25 - 1.35 Quick Ratio 03/31/26 - - 12/31/25 - 0.94 09/30/25 - 1.06 Operating Margin 03/31/26 - -17.56 12/31/25 - -6.95 09/30/25 - -1.65 Net Margin 03/31/26 - -17.56 12/31/25 - -6.95 09/30/25 - -1.65 Pre-Tax Margin 03/31/26 - -17.55 12/31/25 - -6.95 09/30/25 - -1.65 Book Value 03/31/26 - 0.01 12/31/25 - 0.01 09/30/25 - 0.01 Inventory Turnover 03/31/26 - 6.29 12/31/25 - 6.47 09/30/25 - 6.91 Debt-to-Equity 03/31/26 - 0.65 12/31/25 - 0.92 09/30/25 - 0.44 Debt-to-Capital 03/31/26 - 68.62 12/31/25 - 66.86 09/30/25 - 58.88

Powered by Zacks Investment Research ©